Research Papers:

LIMD1 is induced by and required for LMP1 signaling, and protects EBV-transformed cells from DNA damage-induced cell death

Ling Wang, Mary E.A. Howell, Brooke McPeak, Katrina Riggs, Carissa Kohne, Jether Uel Yohanon, Daniel E. Foxler, Tyson V. Sharp, Jonathan P. Moorman, Zhi Q. Yao and Shunbin Ning _

PDF  |  HTML  |  How to cite

Oncotarget. 2018; 9:6282-6297. https://doi.org/10.18632/oncotarget.23676

Metrics: PDF 1767 views  |   HTML 4227 views  |   ?  


Ling Wang1,2, Mary E.A. Howell2, Brooke McPeak2, Katrina Riggs2, Carissa Kohne2, Jether Uel Yohanon2, Daniel E. Foxler3, Tyson V. Sharp3, Jonathan P. Moorman1,2,4, Zhi Q. Yao1,2,4 and Shunbin Ning1,2

1Center of Excellence for Inflammation, Infectious Diseases and Immunity, Quillen College of Medicine, East Tennessee State University, Johnson City 37614, TN, USA

2Department of Internal Medicine, Quillen College of Medicine, East Tennessee State University, Johnson City 37614, TN, USA

3Centre for Molecular Oncology, Barts Cancer Institute, University of London, London EC1M 6BQ, UK

4Hepatitis (HCV/HIV) Program, James H Quillen VA Medical Center, Johnson City 37614, TN, USA

Correspondence to:

Shunbin Ning, email: [email protected]

Keywords: LIMD1; p62; DDR; autophagy; EBV

Received: August 31, 2017     Accepted: December 11, 2017     Published: December 26, 2017


LIMD1 (LIM domain-containing protein 1) is considered as a tumor suppressor, being deregulated in many cancers to include hematological malignancies; however, very little is known about the underlying mechanisms of its deregulation and its roles in carcinogenesis. Epstein-Barr Virus (EBV) is associated with a panel of malignancies of lymphocytic and epithelial origin. Using high throughput expression profiling, we have previously identified LIMD1 as a common marker associated with the oncogenic transcription factor IRF4 in EBV-related lymphomas and other hematological malignancies. In this study, we have identified potential conserved IRF4- and NFκB-binding motifs in the LIMD1 gene promoter, and both are demonstrated functional by promoter-reporter assays. We further show that LIMD1 is partially upregulated by EBV latent membrane protein 1 (LMP1) via IRF4 and NFκB in EBV latency. As to its role in the setting of EBV latent infection, we show that LIMD1 interacts with TRAF6, a crucial mediator of LMP1 signal transduction. Importantly, LIMD1 depletion impairs LMP1 signaling and functions, potentiates ionomycin-induced DNA damage and apoptosis, and inhibits p62-mediated selective autophagy. Taken together, these results show that LIMD1 is upregulated in EBV latency and plays an oncogenic role rather than that of a tumor suppressor. Our findings have identified LIMD1 as a novel player in EBV latency and oncogenesis, and open a novel research avenue, in which LIMD1 and p62 play crucial roles in linking DNA damage response (DDR), apoptosis, and autophagy and their potential interplay during viral oncogenesis.

Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.
PII: 23676